321
Views
4
CrossRef citations to date
0
Altmetric
Research Articles

Computational studies on potential small molecule inhibitors of Leishmania pteridine reductase 1

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 12128-12141 | Received 08 Sep 2022, Accepted 01 Jan 2023, Published online: 12 Jan 2023
 

Abstract

Leishmaniasis is a neglected tropical disease of major public health concern. Challenges with current therapeutics have led to the exploration of plant medicine for potential antileishmanial agents. Despite the promising activity of some antileishmanial natural products, their protein targets have not been explored. The relevance of folate metabolism in the Leishmania parasite’s existence presents crucial targets for the development of antileishmanial chemotherapy. Pteridine reductase 1 (PTR1), a crucial enzyme involved in DNA biosynthesis, is a validated target of the Leishmania parasite. Unearthing inhibitors of this enzyme is therefore an active research area. The goal of this work is to unearth small molecule inhibitors of PTR1 using molecular docking and molecular dynamic simulations. Thus, the interactions between selected antileishmanial natural products and PTR1 were examined. The binding affinities obtained from molecular docking ranged from −6.2 to −9.8 kcal/mol. When compared to the natural PTR1 substrate biopterin, compounds such as anonaine, chimanine D, corynantheine, grifolin, licochalcone A, piperogalin and xylopine produced better binding affinities, making interactions catalytic residues - Tyr194, Asp181, Phe113, Arg17 and Ser111. The PTR1- xylopine, -piperogalin, -grifolin, and -licochalcone A complexes exhibited remarkable stability under dynamic conditions during the entire 200 ns simulation period. The overall binding free energy of grifolin, piperogalin, and licochalcone A were observed to be −105.711, −103.567, and −105.646 kJ/mol respectively. The binding of these complexes was observed to be favorable and spontaneous and as such capable of inhibiting Leishmania PTR1. They could therefore be considered as candidates in the development of antileishmanial chemotherapy.

Communicated by Ramaswamy H. Sarma

Acknowledgement

The authors are grateful to the Center for High Performance Computing, Cape Town, South Africa who granted generous access to the Lengau cluster for the MD simulations.

Disclosure statement

All authors declare that there were no financial, professional, or personal competing interests that might have influenced the performance or presentation of this study.

Author contributions

LSB, AB and ENG conceived the study. All experiments were designed by LSB, AB, JOM and ENG. Computations were made by AB, JOM and ENG. Data analysis was by AB, ENG, JOM and LSB. Manuscript was prepared by AB, and edited by all the authors. All authors read and approved the final manuscript.

Data availability statement

All data generated or analyzed during this study are included in this published article and its supplementary materials.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.